Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease
Proceeds Will Be Used to Progress Lead Program to Phase 1 Clinical Trials and Expand Pipeline Programs CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve…